Content about Cataract

January 21, 2013

Eye care company Alcon has launched a treatment for pain and inflammation resulting from cataract surgery, the company said Monday.

NEW YORK — Eye care company Alcon has launched a treatment for pain and inflammation resulting from cataract surgery, the company said Monday.

The company said Ilevro (nepafenac) ophthalmic suspension was a nonsteroidal anti-inflammatory drug and once-daily treatment for cataract surgery patients.

June 23, 2011

Americans have low sun care 'eye-Q'

According to a recent American Eye-Q survey issued earlier this month, only  32% of Americans understand that the summer sun can do as much damage on the eyes as it does to unprotected skin. Exposure to small amounts of ultraviolet radiation over a period of many years increases the chance of developing cataracts, macular degeneration and eye cancer.

June 3, 2011

Dioptics' Solar Shield Fits Over sunglasses look to protect wearers from UV exposure

Dioptics recently introduced a line of "healthy" sunglasses.

SAN LUIS OBISPO, Calif. — Dioptics recently introduced a line of "healthy" sunglasses.

Solar Shield Fits Over sunglasses are polarized to avoid blinding glare, while blocking 100% UVA/UVB light, Dioptics said.

May 16, 2011

Mylan's generic Xibrom ophthalmic solution enters market

Mylan has launched a generic drug for treating post-operative inflammation in patients who have undergone cataract extraction, the company said Monday.

PITTSBURGH — Mylan has launched a generic drug for treating post-operative inflammation in patients who have undergone cataract extraction, the company said Monday.

Mylan announced the launch of bromfenac ophthalmic solution in the 0.09% strength, for twice-daily administration, under a development and supply agreement with Coastal Pharmaceuticals.

October 17, 2010

Ista gains approval for Bromday

Ista Pharmaceuticals has won approval from the Food and Drug Administration for a drug used...

IRVINE, Calif. Ista Pharmaceuticals has won approval from the Food and Drug Administration for a drug used to treat eye surgery patients.

The drug maker announced the approval of Bromday (bromfenac) ophthalmic solution as a once-daily eye drop for treating pain and inflammation in patients who have received cataract extraction surgery. The drug is a nonsteroidal anti-inflammatory drug, or NSAID, belonging to the same class as the common painkiller ibuprofen. The company plans to launch the drug at the end of this year.

May 2, 2010

Latinos at great risk of developing diabetes-related vision issues, study finds

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease and cataracts than...

BETHESDA, Md. Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease and cataracts than non-Hispanic whites, researchers that were part of the "Los Angeles Latino Eye Study" have found. According to a press release issued by the National Eye Institute on Saturday, these are the first estimates of visual impairment and eye disease development in Latinos.